Saliva test could predict pancreatic cancer

In a small study of three dozen patients, researchers at the UCLA David Geffen School of Medicine found that those with pancreatic cancer had different levels of certain bacteria compared to healthy people. Thirty-one species of bacteria were elevated in the pancreatic cancer group, while 25 other types were depressed. By looking at the results of the study, researchers were able to tell which patients had cancers and which were healthy 80% of the time.

There is currently no screening test for pancreatic cancer, and as a result the disease is usually discovered in its late stages. Just 5% of people with pancreatic cancer are still alive after 5 years. The UCLA researchers say the next step is to determine whether the varied bacterial levels in cancer patients is a cause of or an effect of the disease. A larger study is already underway to clarify the findings. The research was published in the journal Gut.

- check out the article for more

Special Report: 5 promising pancreatic cancer drugs

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.